AU2012326207B2 - Methods and compositions for treating ineffective erythropoiesis - Google Patents

Methods and compositions for treating ineffective erythropoiesis Download PDF

Info

Publication number
AU2012326207B2
AU2012326207B2 AU2012326207A AU2012326207A AU2012326207B2 AU 2012326207 B2 AU2012326207 B2 AU 2012326207B2 AU 2012326207 A AU2012326207 A AU 2012326207A AU 2012326207 A AU2012326207 A AU 2012326207A AU 2012326207 B2 AU2012326207 B2 AU 2012326207B2
Authority
AU
Australia
Prior art keywords
actriib
seq
polypeptide
gdf trap
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012326207A
Other languages
English (en)
Other versions
AU2012326207A1 (en
Inventor
Ravindra Kumar
Robert Scott Pearsall
Jasbir Seehra
Naga Venkata Sai Rajasekhar Suragani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of AU2012326207A1 publication Critical patent/AU2012326207A1/en
Application granted granted Critical
Publication of AU2012326207B2 publication Critical patent/AU2012326207B2/en
Priority to AU2017201580A priority Critical patent/AU2017201580B2/en
Priority to AU2018247262A priority patent/AU2018247262B2/en
Priority to AU2020286229A priority patent/AU2020286229A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012326207A 2011-10-17 2012-10-17 Methods and compositions for treating ineffective erythropoiesis Active AU2012326207B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2017201580A AU2017201580B2 (en) 2011-10-17 2017-03-08 Methods and compositions for treating ineffective erythropoiesis
AU2018247262A AU2018247262B2 (en) 2011-10-17 2018-10-11 Methods and compositions for treating ineffective erythropoiesis
AU2020286229A AU2020286229A1 (en) 2011-10-17 2020-12-09 Methods and compositions for treating ineffective erythropoiesis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161547932P 2011-10-17 2011-10-17
US61/547,932 2011-10-17
PCT/US2012/060650 WO2013059347A1 (en) 2011-10-17 2012-10-17 Methods and compositions for treating ineffective erythropoiesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017201580A Division AU2017201580B2 (en) 2011-10-17 2017-03-08 Methods and compositions for treating ineffective erythropoiesis

Publications (2)

Publication Number Publication Date
AU2012326207A1 AU2012326207A1 (en) 2014-05-15
AU2012326207B2 true AU2012326207B2 (en) 2016-12-15

Family

ID=48141315

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2012326207A Active AU2012326207B2 (en) 2011-10-17 2012-10-17 Methods and compositions for treating ineffective erythropoiesis
AU2017201580A Active AU2017201580B2 (en) 2011-10-17 2017-03-08 Methods and compositions for treating ineffective erythropoiesis
AU2018247262A Active AU2018247262B2 (en) 2011-10-17 2018-10-11 Methods and compositions for treating ineffective erythropoiesis
AU2020286229A Abandoned AU2020286229A1 (en) 2011-10-17 2020-12-09 Methods and compositions for treating ineffective erythropoiesis

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2017201580A Active AU2017201580B2 (en) 2011-10-17 2017-03-08 Methods and compositions for treating ineffective erythropoiesis
AU2018247262A Active AU2018247262B2 (en) 2011-10-17 2018-10-11 Methods and compositions for treating ineffective erythropoiesis
AU2020286229A Abandoned AU2020286229A1 (en) 2011-10-17 2020-12-09 Methods and compositions for treating ineffective erythropoiesis

Country Status (13)

Country Link
US (4) US20130243743A1 (OSRAM)
EP (3) EP2797620B1 (OSRAM)
JP (4) JP6092883B2 (OSRAM)
KR (4) KR102079482B1 (OSRAM)
CN (3) CN107837390A (OSRAM)
AU (4) AU2012326207B2 (OSRAM)
BR (3) BR112014009528B1 (OSRAM)
CA (1) CA2852683A1 (OSRAM)
DK (2) DK3875104T3 (OSRAM)
EA (2) EA034563B1 (OSRAM)
ES (3) ES3010483T3 (OSRAM)
HK (2) HK1250341A1 (OSRAM)
WO (1) WO2013059347A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551852T3 (es) 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CA3039330C (en) 2007-02-09 2021-11-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5922928B2 (ja) 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを高めるためのｇｄｆトラップの使用
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
CA2773494A1 (en) * 2009-09-09 2011-03-17 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
KR102520970B1 (ko) * 2014-03-21 2023-04-12 악셀레론 파마 인코포레이티드 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법
JP6649895B2 (ja) * 2014-04-18 2020-02-19 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
AU2015274277B2 (en) * 2014-06-13 2021-03-18 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
SMT202300166T1 (it) * 2014-12-03 2023-07-20 Celgene Corp Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
RS61881B1 (sr) 2015-04-22 2021-06-30 Biogen Ma Inc Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića
HK1251157A1 (zh) * 2015-05-13 2019-01-25 细胞基因公司 使用ACTRII配体陷阱治疗β-地中海贫血
EP4190805A3 (en) 2015-05-20 2023-08-16 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
MX2019001043A (es) 2016-07-27 2019-09-26 Acceleron Pharma Inc Metodos y composiciones para el tratamiento de la mielofibrosis.
WO2018067874A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
EP3538123A4 (en) 2016-11-10 2020-10-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE
JP7496686B2 (ja) * 2017-06-14 2024-06-07 セルジーン コーポレイション 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN120399032A (zh) 2018-01-12 2025-08-01 科乐斯疗法公司 激活素受体iib型变体及其使用方法
EP3790572A4 (en) 2018-05-09 2022-03-16 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011020045A1 (en) * 2009-08-13 2011-02-17 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
CA2217545A1 (en) 1995-04-11 1996-10-17 Marc Vidal Reverse two-hybrid systems
US5807839A (en) * 1997-04-15 1998-09-15 Advanced Viral Research Corp. Method for stimulating red blood cell production
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
MXPA05003889A (es) * 2002-10-15 2005-06-22 Celgene Corp Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
ES2551852T3 (es) 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
JP5922928B2 (ja) * 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを高めるためのｇｄｆトラップの使用
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011020045A1 (en) * 2009-08-13 2011-02-17 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Also Published As

Publication number Publication date
US20170137791A1 (en) 2017-05-18
US20170327800A1 (en) 2017-11-16
AU2017201580A1 (en) 2017-03-30
EP3520805B1 (en) 2021-03-10
CN107693776A (zh) 2018-02-16
EP2797620A4 (en) 2015-05-20
CN103987403B (zh) 2017-12-01
AU2017201580B2 (en) 2018-07-12
CN103987403A (zh) 2014-08-13
BR122019023166B1 (pt) 2021-02-23
US20130243743A1 (en) 2013-09-19
JP6796626B2 (ja) 2020-12-09
DK3520805T3 (da) 2021-04-19
AU2018247262B2 (en) 2020-12-24
CN107837390A (zh) 2018-03-27
EA202090053A2 (ru) 2020-04-30
EA202090053A3 (ru) 2020-06-30
BR112014009528B1 (pt) 2020-12-29
HK1203413A1 (en) 2015-10-30
KR20220075438A (ko) 2022-06-08
AU2012326207A1 (en) 2014-05-15
EA201490809A1 (ru) 2014-09-30
EP3520805A1 (en) 2019-08-07
EP2797620A1 (en) 2014-11-05
AU2020286229A1 (en) 2021-01-07
KR102079482B1 (ko) 2020-02-19
BR122019023174B1 (pt) 2021-02-23
KR20190105113A (ko) 2019-09-11
BR112014009528A8 (pt) 2019-12-10
EP2797620B1 (en) 2019-04-24
EA034563B1 (ru) 2020-02-20
WO2013059347A1 (en) 2013-04-25
JP2014530253A (ja) 2014-11-17
JP2020186277A (ja) 2020-11-19
ES3010483T3 (en) 2025-04-03
US20210207107A1 (en) 2021-07-08
JP6092883B2 (ja) 2017-03-08
EP3875104B1 (en) 2025-01-22
HK1252940A1 (zh) 2019-06-06
AU2018247262A1 (en) 2018-11-01
ES2869168T3 (es) 2021-10-25
DK3875104T3 (da) 2025-02-03
CA2852683A1 (en) 2013-04-25
KR20140084211A (ko) 2014-07-04
KR20200019261A (ko) 2020-02-21
JP6383821B2 (ja) 2018-08-29
ES2741477T3 (es) 2020-02-11
JP2018165287A (ja) 2018-10-25
HK1250341A1 (zh) 2018-12-14
JP2017101060A (ja) 2017-06-08
EP3875104A1 (en) 2021-09-08
BR112014009528A2 (pt) 2017-05-09

Similar Documents

Publication Publication Date Title
US10889626B2 (en) Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
AU2018247262B2 (en) Methods and compositions for treating ineffective erythropoiesis
AU2010282361B2 (en) Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
AU2009282441B2 (en) Use of GDF traps to increase red blood cell levels
AU2017204230B2 (en) Use of GDF traps to increase red blood cell levels
AU2021209153A1 (en) Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)